Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Esketamine for Treatment-Resistant Bipolar Depression
NCT03965871Phase 2Completed
- Sponsor
- Celon Pharma S.A.
- Start
- Mar 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of esketamine in bipolar disorder (BD), sponsored by Celon Pharma S.A.. Started Mar 2019; status: completed.
02
Drugs
esketamine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT03965871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03965871.